Answers are grounded in this paper and cite their sources.
// Yu Fang 1 , Jingxuan Wang 1 , Feng Wu 2 , Ying Song 1 , Shu Zhao 1 and Qingyuan Zhang 1 1 Department of Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Nangang District, Harbin 151000, Heilongjiang Province, China 2 Department of Gastroenterology, The First Affiliated Hospital of Harbin Medical University, Nangang District, Harbin 151000, Heilongjiang Province, China Correspondence to: Qingyuan Zhang, email: qyzhangdoctor@sina.com Keywords: LncRNA-HOXA-AS2, miR-520c-3p, breast cancer, growth, metastasis Received: January 16, 2017 Accepted: March 01, 2017 Published: May 02, 2017 ABSTRACT The long non-coding RNA (lncRNA) HOXA cluster antisense RNA2 (HOXA-AS2) has recently been shown to be dysregulated and involved in the progression of several cancers. However, the biological role and clinical significance of HOXA-AS2 in the carcinogenesis of breast cancer are still unclear. In the present study, we found that HOXA-AS2 was up-regulated in human breast cancer tissues and cell lines and associated with clinicopathological characteristics. Silencing of HOXA-AS2 inhibited the progression of breast cancer cells in vitro and in vivo . Furthermore, microarray profiling indicated that HOXA-AS2 serves as an endogenous sponge by directly binding to miR-520c-3p and down-regulating miR-520c-3p expression. We demonstrated that HOXA-AS2 controls the expression of miR-520c-3p target genes, TGFBR2 and RELA, in breast cancer cells. Therefore, our study may provide a better understanding of the pathogenesis of breast cancer and suggests that HOXA-AS2 may be a potential prognostic and therapeutic target in breast cancer.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: